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Relationship between Vancomycin Trough Concentrations and
Nephrotoxicity: a Prospective Multicenter Trial䌤
John A. Bosso,1,2* Jean Nappi,1 Celeste Rudisill,1 Marlea Wellein,3 P. Brandon Bookstaver,1
Jenna Swindler,4 and Patrick D. Mauldin1
Department of Clinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy, Charleston and Columbia,
South Carolina1; Division of Infectious Diseases, Medical University of South Carolina College of Medicine, Charleston,
South Carolina2; Department of Pharmacy, Trident Medical Center, Charleston, South Carolina3; and
Department of Pharmacy Services, McLeod Regional Medical Center, Florence, South Carolina4

Several single-center studies have suggested that higher doses of vancomycin, aimed at producing trough
concentrations of >15 mg/liter, are associated with increased risk of nephrotoxicity. We prospectively assessed
the relative incidence of nephrotoxicity in relation to trough concentration in patients with documented
methicillin-resistant Staphylococcus aureus (MRSA) infections at seven hospitals throughout South Carolina.
Adult patients receiving vancomycin for at least 72 h with at least one vancomycin trough concentration
determined under steady-state conditions were prospectively studied. The relationship between vancomycin
trough concentrations of >15 mg/ml and the occurrence of nephrotoxicity was assessed using univariate and
multivariate analyses, controlling for age, gender, race, dose, length of therapy, use of other nephrotoxins
(including contrast media), intensive care unit (ICU) residence, episodes of hypotension, and comorbidities.
Nephrotoxicity was defined as an increase in serum creatinine of 0.5 mg/dl or a >50% increase from the
baseline for two consecutive measurements. MICs of vancomycin for the MRSA isolates were also determined.
A total of 288 patients were studied between February 2008 and June 2010, with approximately one-half having
initial trough concentrations of >15 mg/ml. Nephrotoxicity was observed for 42 patients (29.6%) with trough
concentrations >15 mg/ml and for 13 (8.9%) with trough concentrations of <15 mg/ml. Multivariate analysis
revealed vancomycin trough concentrations of >15 mg/ml and race (black) as risk factors for nephrotoxicity
in this population. Vancomycin trough concentrations of >15 mg/ml appear to be associated with a 3-fold
increased risk of nephrotoxicity.
determined that the necessary doses to achieve a target therapeutic area under the curve (AUC)/MIC ratio of ⱖ400 for
organisms with an MIC of 2 mg/liter would be associated with
a 35% incidence of nephrotoxicity (26). This literature, including a number of studies available only in abstract form, has
been nicely summarized and critically reviewed by the laboratory of Wong-Beringer et al. (36).
As acute renal injury or failure, regardless of cause, is associated with significant increases in hospital costs, length of stay,
and mortality (8), it is important to resolve this issue. We
completed a prospective, multicenter evaluation of the relationship between the incidence of nephrotoxicity and vancomycin trough concentrations to help clarify this issue.
(This work was presented in part at the Infectious Diseases
Society of America Annual Meeting, Vancouver, British Columbia, Canada, October 2010 [abstract 290].)

Staphylococcus aureus has become a major cause of serious
infections in both community and institutional settings, with
methicillin-resistant strains causing numerous invasive infections, especially those involving the bloodstream (2, 13, 34).
Due to concerns with efficacy as they relate to adequacy of
dosing and related plasma concentrations, it is currently commonplace to administer vancomycin in doses intended to
achieve trough concentrations of 15 mg/liter or higher in the
treatment of methicillin-resistant S. aureus (MRSA) infections.
A consensus paper published in 2009 recommended that patients be dosed with this end in mind (30). Some practitioners
have extrapolated these dosing recommendations with associated trough concentration goals to all vancomycin use. However, evidence of superior efficacy is lacking, and results of
several single-center, mostly retrospective trials have suggested
that this more aggressive dosing may be related to an increased
incidence of vancomycin-related nephrotoxicity (12, 14, 18, 20,
27) and ototoxicity (9). The results and conclusions of these
studies have been questioned, to varying degrees, due to design
limitations, including the failure to account for other risk factors for renal compromise, and/or their single-center nature.
Another relevant study, using Monte Carlo simulations and
considering various dosing regimens and staphylococcal MICs

MATERIALS AND METHODS
The primary objective of this study was to determine if there is a difference in
the incidence of nephrotoxicity associated with high vancomycin trough concentrations (⬎15 mg/liter) and that associated with lower trough concentrations
(ⱕ15 mg/liter). Secondary objectives were to identify patient characteristics/risk
factors, if any, that are associated with vancomycin nephrotoxicity, and to characterize the distribution of MICs of vancomycin for MRSA in South Carolina.
This was a multicenter, prospective, observational trial, and included both
teaching and community hospitals from throughout the state of South Carolina
(Table 1). The study protocol was approved by the Institutional Review Board at
each participating institution. Patients included were at least 18 years of age, had
documented MRSA infections, received vancomycin for at least 72 h, had baseline (pre-vancomycin) and intratherapy serum creatinine determined, and had at
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TABLE 1. Participating institutions
Hospital no.

Hospital type

No. of beds

No. of patients
enrolled

1
2
3
4
5
6
7

Community
Academic
Community
Community/academic
Community
Community/academic
Community

453
709
453
588
296
650
167

33
90
13
19
16
100
20

least one steady-state (2 to 4 days into therapy) vancomycin trough concentration
determined. In cases in which more than one vancomycin trough was determined, an “average” weighted value, based on theoretical days at the various
concentrations, was calculated in order to classify the patient as having a high or
low trough. Exclusion criteria consisted of patients with concomitant amphotericin B or regularly scheduled nonsteroidal anti-inflammatory therapy, a history of
receiving vancomycin for at least 72 h in the 30 days prior to inclusion in this
study, a recent rise in serum creatinine (ⱖ25% or 0.3 mg/dl from the baseline),
a history of receiving any form of renal replacement therapy, neutropenia (absolute neutrophil count of ⬍1,000 cells/mm3), or cystic fibrosis. Nephrotoxicity
was defined, for the purposes of this study, as an increase in serum creatinine of
0.5 mg/dl or a ⱖ50% increase from the baseline serum creatinine level for two
consecutive laboratory determinations.
Patients enrolled in the study were dosed with vancomycin per the standard of
care at each participating institution (per the prescribing physician, and/or protocol, and/or clinical pharmacist). The study methods did not include specific
dosing guidelines or drug monitoring. An investigator observed the patients daily
during their course of vancomycin therapy until vancomycin therapy was discontinued or the patient was discharged from the hospital, depending upon which
occurred first. During the observation period, demographic information, including gender, race, age, and weight, were recorded along with the infection type
(e.g., pneumonia) and whether it was community or hospital associated. The site
of the positive MRSA culture (e.g., blood) was also noted. Total daily vancomycin doses and initial dosing frequency were recorded, as were all vancomycin
trough concentration determinations. Additionally, exposure to other known risk
factors for renal injury was noted on a daily basis. These risk factors included
receipt of nephrotoxic agents, including radiographic contrast agents, aminoglycosides, cyclosporine A, tacrolimus, nonsteroidal inflammatory agents, and
COX-2 inhibitors, as well as angiotensin converting enzyme inhibitors (ACEIs)
and angiotensin receptor blocking (ARB) agents, which are known to raise
serum creatinine. Any episodes of hypotension (systolic blood pressure of less
than 90 mm Hg) and residence in an intensive care unit (ICU) were noted daily.
Finally, comorbidity information was collected for all patients to allow for determination of Charlson scores (4). Patients discharged with vancomycin to be
administered outside the hospital did not have further information collected
after discharge.
To characterize the distribution of MICs of vancomycin for MRSA, the MICs
of all MRSA isolates from patients enrolled in the study were determined with
by Etest according to manufacturer’s instructions. The Etests were performed in
the microbiology laboratory of the hospital where the specimens were collected.
After standard test completion, a digital image was recorded and sent in a secure
fashion to the principal investigator for interpretation.
To protect patient confidentiality, each patient was assigned a study number at
each respective participating institution. Only the participating coinvestigator
had access to the number code and the study data. Study data were transmitted
to the principal investigator utilizing a secure server, where a new subject number
was assigned.
Sample size determination and statistical analysis. A sample size of 223 per
group (high and low trough concentrations) was originally estimated as that
needed to detect an increase in nephrotoxicity from 5% to 12% with vancomycin
trough concentrations of ⱕ15 and ⬎15 mg/liter, respectively, with 80% power
and an ␣ of 0.05 using a one-tailed test based on the relevant literature published
prior to the present study. Based on an interim analysis of the data, it was clear
that far fewer patients would be needed. At 12 months, we had enrolled 135
patients with a fairly equal distribution of low and high vancomycin trough
concentrations (representing well over 1/3 of the revised projected total enrollment). The interim analysis was based upon the first 103 patients enrolled. Of
these, 23 had met our definition of nephrotoxicity and 18 (78%) had vancomycin

trough concentrations above 15 mg/liter. Thus, the preliminary rates of vancomycin-related nephrotoxicity for those with trough concentrations above and
equal to or less than 15 mg/liter were 31 and 12%, respectively. It should be
noted, however, that this interim analysis did not take into account other risk
factors for renal toxicity/compromise which were considered in our final analysis.
Based on this analysis we projected a needed sample size of 83 per treatment
group (before consideration of covariates) to detect the originally proposed
difference in rates of nephrotoxicity (5 versus 12%) with vancomycin trough
concentrations of ⱕ15 and ⬎15 mg/ml, respectively, with 80% power and an ␣ of
0.05 using a two-tailed test. We assumed that approximately 50% of patients
enrolled in the study would continue to fall into each of the two groups (high and
low trough concentrations). We continued to monitor our enrollment to evaluate
this assumption and considered it prudent to continue enrollment for an addition
6 months to ensure similarly sized groups and adequate statistical power when
controlling for other risk factors for renal compromise.
Both univariate and multivariate analyses were performed. For the univariate analysis, a chi-square test was used. Logistic regression was used for the
multivariate analyses with nephrotoxicity (binary) serving as the dependent
variable, and high vancomycin concentrations (⬎15 mg/liter) serving as the
primary independent variable. Covariates included age, race, gender, hypotension, receipt of other nephrotoxic agents, length of vancomycin therapy,
vancomycin dose per kg of body weight, ICU stay, and comorbidities. For the
multivariate analysis, multicolinearity was assessed utilizing Pearson correlation coefficients. If independent variables were found to be highly correlated,
they were dropped from the multivariate analysis. Levels and amounts (numbers of correlated variables) of correlations, as well as clinical input, determined this decision process. Similarly, comorbidities that rarely were present
in the study population (i.e., ⬍1%) were also dropped from the model.
Statistical significance was determined at the 5% level. Microsoft Excel 2008
and SAS 9.1 were used for the statistical analysis.

RESULTS
Data were obtained for 291 patients, of which 166 were
male, 183 white, and 97 African-American. The mean age (⫾
standard deviation [SD]) was 55 (⫾17) years. Data were adequate, for purposes of our analysis, for 288 patients (the excluded patients had one or no serum creatinine determinations). Numbers enrolled from each participating hospital are
included in Table 1, and more detailed patient demographics
and study characteristics are presented in Table 2. Of the 288
evaluable patients, 206 were deemed to have hospital-acquired
MRSA infections. The most common infections were wound
infections, pneumonia, and bacteremia, with the vast majority
confined to a single type. The average length of vancomycin
therapy was 210 h or 9 days (median, 180 h or 7.5 days). One
hundred sixteen received at least one other nephrotoxin,
ACEI, or ARB agent during the course of vancomycin therapy.
Of these, 24 patients received two such agents while two received three. The most commonly received were ACEIs and
ARB agents. Twenty-five patients received contrast media.
Fifty-four patients experienced one or more episodes of hypotension.
Fifty-five patients met the definition of nephrotoxicity,
with 42 of these being in the high trough concentration
group, reflecting incidences of 8.9 and 29.6% in the low and
high trough concentration groups, respectively. Univariate
analysis using a chi-square test with the occurrence of nephrotoxicity as the dependent variable and a trough concentration of ⬎15 mg/liter as the independent variable revealed
a highly significant and positive relationship (P ⬍ 0.0001).
Pearson correlation coefficients determined a high correlation between length of vancomycin therapy and vancomycin
dose per kg of body weight (correlation coefficient, 0.719;
P ⬍ 0.0001), dictating inclusion of only one of these in the
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TABLE 2. Demographics and characteristics for patients with and
without nephrotoxicity
No. (%) of patients or no. of days
Characteristic

Nephrotoxicity
group

Nonnephrotoxicity
group

Total no. of patients
Male gender

55
28 (51)

233
137 (59)

Race
White
Black
Other

29 (53)
26 (47)
0

154 (166)
71 (30)
8 (4)

Hospital-associated infection
Avg total vancomycin dose (g)a
Avg length of vancomycin
therapy (days)
No. with initial dosing frequency
of every 12 h (n ⫽ 256)
Trough concn, ⬎15 mg/liter
Trough concn, ⱕ15 mg/liter
Receipt of ⱖ1 nephrotoxin
Receipt of ⱖ2 nephrotoxins
Avg no. of days other
nephrotoxin receivedb
Hypotensive episode
Average no. of days with
hypotensive episodesc
ICU stay
Avg no. of ICU daysd
Any comorbiditiese
Avg Charlson scoree
Infection type
Wound
Pneumonia
Bacteremia

44 (80)
19,749
10.6

161 (69)
18,769
8.3

39 (76)

146 (72)

41 (75)
14 (25)
26 (47)
6 (10.9)
7

101 (43)
132 (57)
90 (39)
18 (7.7)
6.2

11 (21)
3.3

43 (18)
2.7

23 (42)
9.6
36 (66)
1.8

73 (31)
6.9
132 (57)
1.2

16 (29)
14 (25)
12 (22)

91 (39)
68 (29)
48 (21)

a

Total dose (in grams) for period of observation.
For those receiving another nephrotoxin(s).
For those having ⱖ1 day(s) with hypotension.
d
For those who stayed in the ICU ⱖ1 day(s).
e
Per Charlson et al. (4).
b
c

final model. As data relating to length of therapy were more
complete, we chose to drop dose per kg of body weight from
the final analysis. Multivariate analysis utilizing logistic regression and controlling for other risk factors and patient
characteristics confirmed the strong relationship between
nephrotoxicity and trough concentrations of ⬎15 mg/liter
(odds ratio, 3.643; 95% confidence interval [CI], 1.749 to
7.587) (Table 3). The higher the initial trough concentration
for vancomycin, the more likely the occurrence of nephrotoxicity. The incidence of toxicity in those with initial trough
concentrations of ⱖ20 mg/liter, ⱖ25 mg/liter, and ⱖ30 mg/
liter were 32, 45, and 50%, respectively. Another factor
statistically relating to the occurrence of toxicity was race
(odds ratio, 2.589; 95% CI, 1.278 to 5.244) with a higher
incidence in blacks (versus whites). Comorbidities associated with toxicity are shown in Table 3.
MICs were determined for 288 isolates from 277 patients. In
generating descriptive statistics, only one isolate from each
patient, the first isolated, was included, regardless of any apparent MIC differences. The mean, median, and modal MIC
for these 277 isolates was 1.5 mg/liter.
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TABLE 3. Results of multivariate analysisa
Variable

Odds ratio for
nephrotoxicity

95% CI

Trough concn, ⬎15 mg/liter
Hypotension
LOT with vancomycin
Other nephrotoxins given
Gender (male)
Race (black)
ICU stay
Age
Cerebrovascular disease
Myocardial infarction
Peripheral vascular disease
Ulcer disease
Heart failure
Diabetes without end organ damage
Hemiplegia
Any tumor
Mild hepatic disease
Moderate hepatic disease
Metastatic solid tumor
AIDS

3.643
1.055
1.002
1.201
0.986
2.589
1.408
0.999
0.253
0.284
2.326
1.283
3.666
1.038
1.079
1.153
3.856
0.280
5.877
0.697

1.749–7.587
0.444–2.503
1.000–1.004
0.606–2.381
0.488–1.995
1.278–5.244
0.700–2.834
0.978–1.020
0.051–1.243
0.027–2.965
0.402–13.456
0.217–7.574
1.017–13.208
0.512–2.104
0.106–10.946
0.313–4.249
0.179–83.135
0.021–3.716
1.370–25.204
0.032–15.063

a
Shown are results of multivariate analysis (n ⫽ 280). Eight observations were
deleted from the multivariate model due to missing values. LOT, length of
therapy.

DISCUSSION
Despite a report of a recent decline in invasive MRSA infections (15), this pathogen remains a major cause of serious
infection. The pathogen is encountered mainly in health careassociated infections, although onset is common in both institutional and community settings (16). S. aureus infections, particularly those with MRSA, are associated with significantly
increased morbidity, mortality, lengths of hospital stays, and
health care costs (1, 5, 7, 11, 25), which are sometimes explained by inadequate initial therapy (16).
Inadequacy of therapy could be due to failure to consider S.
aureus as a causative pathogen, failure to consider methicillin
resistance, or subtherapeutic dosing of vancomycin. Some
studies have suggested that higher vancomycin MICs for
MRSA relate to higher treatment failure rates (3, 10, 12, 19,
32), and we know that certain risk factors, such as previous
vancomycin therapy and ICU stay, are associated with infection with these species (21, 23). Further, there have been
reports, from single institutions, indicating a rise in average
vancomycin MICs over time (28, 33, 35).
It has been determined that the parameter best relating to
the antibacterial effect of vancomycin is the pharmacodynamic
parameter AUC/MIC (6, 29). The apparent target associated
with superior response rates is an AUC at 24 h (AUC24)/MIC
of ⱖ400 (24). However, traditional doses of vancomycin (1 g
every 12 h) are unlikely to achieve this target in adults with
normal renal function and vancomycin MICs above 1 mg/liter.
The observations of rising vancomycin MICs in MRSA, decreasing clinical response associated with those higher MICs,
together with those regarding the drug’s pharmacodynamics,
has led many to theorize the need for higher doses. In fact, the
aforementioned consensus statement recommends doses to
achieve vancomycin trough concentrations of 10 to 20 mg/liter
for treatment of MRSA infections. This necessitates higher
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doses, and the specter of vancomycin-related nephrotoxicity
has once again emerged. A number of single-center studies
have explored this issue (12, 14, 18, 20, 27). They have focused
on either trough concentrations or the magnitude of total daily
dose, and most determined that it is the trough concentration
that best describes the drug exposure-toxicity relationship (22),
although a study by Lodise et al. reported an association with
total daily doses of ⱖ4 g (20). While higher rates of nephrotoxicity (11 to 35%) were observed in these studies, higher
rates of clinical cure were not observed for those with trough
concentrations of ⱖ15 mg/liter. As these studies reported single-center experiences, in some cases were retrospective in
design, and in others failed to consider other risk factors for
renal injury, the present study was undertaken.
We found a statistically significant and positive relationship
between the occurrence of nephrotoxicity and vancomycin
trough concentrations of greater than 15 mg/liter, even when
accounting for other risk factors. Our findings support the
observations of previous, single-center studies in terms of
trough concentrations greater than 15 mg/liter being related to
higher rates of toxicity. Also, we are not the first to observe a
rising rate of nephrotoxicity with rising trough concentrations
(18). However, we did not corroborate the finding of others
that concomitant administration of other nephrotoxins accentuated this risk. Lodise et al. also did not detect a contribution
of concomitant aminoglycoside therapy to vancomycin-induced nephrotoxicity (20). However, it is important to note
that in examining absolute differences in rates or percentages
with various risk factors in the groups with and without toxicity,
a consistent trend for higher incidence was observed in the
toxicity group although not to a statistically significant degree
(Table 2). We are unable to explain the apparent association
between race and vancomycin-induced nephrotoxicity.
The finding that higher vancomycin dosing resulting in
higher vancomycin concentrations leads to an increased risk of
nephrotoxicity does not necessarily pose an argument against
that practice. The consensus statement published in 2009 recommended the practice based upon potential failure to achieve
putative pharmacodynamic targets with traditional dosing, especially for MRSA isolates with higher MICs (30). Further, it
could be argued that higher vancomycin dosing has already
become a standard of care, at least in the setting of MRSA
infections. Further, a recently published study provides evidence supporting the higher dosing practice from an efficacy
standpoint (18). Nonetheless, our findings draw attention to
the increased risk of this side effect and the apparent need to
carefully monitor renal function in patients in which this dosing
strategy is employed.
Finding a mean (also median and mode) MRSA MIC of 1.5
mg/liter in a state-wide study is noteworthy. However, with no
previous data available for comparison, this indicates only what
the situation was at the time of specimen collection. Whether
this represents an increase from previous years is open to
speculation only, regardless of likelihood. Further, our findings
should also be interpreted with the knowledge that the methodology employed, while practical for this study, is known to
provide results systematically higher than with the reference
broth microdilution method (31). Even if our modal MIC were
truly 1 mg/liter, that value is perhaps higher than it was in
earlier years and thus may have implications for empirical
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antibiotic therapy because, as already mentioned, a decreased
therapeutic response to vancomycin (regardless of dose) has
been observed for patients infected with strains exhibiting
higher (1.5 to 2 mg/liter) MICs, including heterogeneous vancomycin-intermediate S. aureus (hVISA) strains which are not
detected with routine testing (6, 20–22).
A number of limitations of this study should be appreciated.
Almost two-thirds of the patients included were hospitalized at
two institutions. While these were the two largest hospitals,
they represented 41% of the summed bed capacity of all participating centers. It is possible that differences in patient types
and acuity in these two hospitals influenced our results to some
degree. However, we were not able to demonstrate any interinstitutional influences within our results (data not shown).
Due to the observational nature of the study, we were not
always able to monitor patients through the conclusion of their
course of vancomycin therapy (when completed at home or at
another health-care facility). Therefore, our ability to completely and accurately assess the influence of length of therapy
and total cumulative dose of vancomycin on nephrotoxicity was
somewhat compromised and we could not assess time to recovery of normal renal function. It has been noted by other
investigators that nephrotoxicity is related to total daily and
therefore, possibly, cumulative dose (20). To attempt to corroborate this observation, it would be necessary to monitor
renal function daily until the time that the definition of toxicity
was first noted so that total cumulative dose leading up to
toxicity could be accurately determined. One could speculate
that toxicity may be better related to exposure, which would be
better quantified as area under the plasma concentration versus time curve (rather than cumulative dose or trough concentrations). Our observational study did not allow this, as a dayto-day determination of each patient’s pharmacokinetics
would have been necessary. Also, it could be argued that our
method of assigning patients with multiple trough determinations to the high or low trough concentration group was less
than ideal. Without daily determinations, it would be difficult
to determine an average or median trough concentration.
However, our weighting method did allow classification based
on whether the trough concentration was high or low for the
majority of days of observation. We did not fully quantitate
some of the risk factors for renal injury. For example, an
episode of hypotension was simply predicated on a systolic
blood pressure of ⱕ90 mm Hg being recorded in the patient’s
chart. Information regarding length of the episode was not
available. This may partially explain the lack of a statistically
significant association between this risk factor and the occurrence of nephrotoxicity. Similarly, while the use of other nephrotoxins, ACEIs and ARB agents, including their number, was
recorded, we did not quantify length of exposure for individual
agents. Again, this may help explain our failure to corroborate
an influence on occurrence of nephrotoxicity. Recommendations for more ideal studies of this issue have recently been
published elsewhere (36).
In summary, this multicenter, prospective study supports
previous reports of an increased risk of vancomycin-associated
nephrotoxicity in patients with trough concentrations above 15
mg/liter independently of other known risk factors for renal
injury. Renal function should be carefully and regularly mon-
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itored in patients receiving doses intended to produce these
higher trough concentrations.
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